News

Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far?

Thursday, 29 April 2021

A team at the University of York recently published a study in which they sought to generate more reliable evidence to inform the estimation of marginal productivity in the NHS. In our response, published in Medical Decision Making, we suggest that, unfortunately, the estimates provided by the ‘experts’ in the study are of little practical use.

Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic

Wednesday, 21 April 2021

In this blog, we reflect on some of the key learnings from the recent pull and push strategies to develop COVID-19 vaccines in the UK, the US, and the European Union. We use our recent work on portfolio management, pricing, and procurement of COVID-19 vaccines (forthcoming as an OHE report) to organise the review.

Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions?

Wednesday, 14 April 2021

A new paper explores the equivalence of Multi-Criteria Decision Analysis and Augmented Cost-Effectiveness Analysis in adding elements of value to QALY-based cost-effectiveness decision making. It finds that they are equivalent methods under reasonable assumptions when elements of value can be aggregated into two separate top-level groups: health and financial.

Vacancy Economist

Tuesday, 6 April 2021

The Office of Health Economics (www.ohe.org) wishes to recruit a well-qualified, highly motivated and energetic junior economist, with particular strengths in health economics, including the economics of health technology assessment, health care systems and/or the life sciences industry.

Ethical Goals and Design Criteria for ‘Fair Access” to Drugs in the US Health Care System

Wednesday, 31 March 2021

In the contentious debate around US drug prices, less well understood is: if the price of a drug is a fair, value-based, price, how we assess if insurance coverage provides patients with ‘fair access’ to that drug? This paper from ICER and OHE authors seeks to define fair access. It proposes Ethical Goals for Access and Fair Design Criteria for cost-sharing and prior authorisation protocols.

News

Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far?

Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic

Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions?

Vacancy Economist

Ethical Goals and Design Criteria for ‘Fair Access” to Drugs in the US Health Care System

Pages

Recent Posts

News categories

Sign Up
for
OHE
Updates

Read
about
our
research

Learn
about
our
consulting